TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01505569
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
Study: NCT00163657
Drug: Daclizumub
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anti-rejection drug
Study: NCT00163657
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti rejection drug
Study: NCT00163657
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti rejection drug
Study: NCT00163657
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti rejection drug
Study: NCT04362566
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
Study: NCT01211327
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 2% eye drops
Study: NCT01211327
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0,1% eye drops
Study: NCT00325728
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
Study: NCT01505569
Drug: Ursodiol
Normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
Study: NCT00685607
Drug: loperamide-simethicone
Normalized name: loperamide-simethicone
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
Study: NCT02256683
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
Study: NCT02256683
Drug: Phenprocoumon
Normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
Study: NCT00034905
Drug: quetiapine fumarate vs risperidone
Normalized name: Quetiapine Fumarate
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00003484
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02430311
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet-150mg, Oral
Study: NCT02430311
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection
Study: NCT00003484
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02430311
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet-100mg, Oral
Study: NCT02215720
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02215720
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03532035
Drug: Brincidofovir
Normalized name: Brincidofovir
DrugBank: Brincidofovir (DB12151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
Study: NCT01859858
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03921021
Drug: Telomelysin
Normalized name: Telomelysin
DrugBank: Suratadenoturev (DB18672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
Study: NCT01534663
Drug: Glutamine and Fish Oil Supplementation
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
Study: NCT01818024
Drug: Single IV dose of GSK2862277
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2862277 solution available in a 40 mg vial for IV administration.
Study: NCT01818024
Drug: Single IH dose of GSK2862277
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
Study: NCT01818024
Drug: Repeat IV dose of GSK2862277
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2862277 solution available in a 40 mg vial for IV administration.
Study: NCT01818024
Drug: Repeat IH dose selected of GSK2862277 from Part 2
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
Study: NCT00005870
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005870
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005870
Drug: rubitecan
Normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02907983
Drug: Stellate Ganglion Block Injection with Bupivicaine
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study: NCT02907983
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study: NCT03600805
Drug: Sarilumab SAR153191
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT03600805
Drug: Sarilumab matching placebo
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT03600805
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablets or capsules Route of administration: oral administration
Study: NCT03600805
Drug: Prednisone matching placebo
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsules Route of administration: oral administration
Study: NCT03732235
Drug: FOLFIRI+Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antiangiogenic factor
Study: NCT02537171
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
Study: NCT00840398
Drug: Buspirone Hydrochloride 30 mg Tablet
Normalized name: buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 30 mg, single-dose fed
Study: NCT03040362
Drug: [14C]-lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: \[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
Study: NCT01515592
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
Study: NCT03217175
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
Study: NCT01515592
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
Study: NCT01515592
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
Study: NCT00377260
Drug: amoxicillin-clavulanate
Normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
Study: NCT00128791
Drug: Nitroprusside
Normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00159861
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01988610
Drug: 28 days treatment with Mifepristone.
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01153347
Drug: TC-5214
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT02567487
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transversus abdominis plane block with levobupivacaine
Study: NCT01665183
Drug: ADI-PEG 20
Normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00418353
Drug: Betamethasone(Celestone soluspan) and Dexamethasone
Normalized name: Dexamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02401828
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Switch from combination antiretroviral therapy to dolutegravir monotherapy
Study: NCT00472433
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01631136
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m²
Study: NCT01631136
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m²
Study: NCT01631136
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m²
Study: NCT01631136
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m²
Study: NCT03099187
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 267 mg capsules three times in a day.
Study: NCT00003003
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003003
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00378547
Drug: paracetamol + pregabalin + placebo
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
Study: NCT00378547
Drug: paracetamol + pregabalin + dexamethasone
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
Study: NCT01647971
Drug: Ublituximab
Normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
Study: NCT01317433
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/m² IV infusion of 60 minutes every 15 days
Study: NCT00307996
Drug: Coenzyme Q10 (drug)
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002601
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
Study: NCT00002601
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
Study: NCT00002601
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
Study: NCT04343001
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 150mg
Study: NCT04343001
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 100mg
Study: NCT00214370
Drug: Propofol alone
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00254462
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
Study: NCT02244502
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
Study: NCT02431351
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
Study: NCT01290874
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium bromide 18 mcg once daily for one year of treatment.
Study: NCT01290874
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol 50 mcg twice daily for one year of treatment.
Study: NCT01290874
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol 12 mcg twice daily for one year
Study: NCT00601536
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01195727
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01311050
Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
Study: NCT04227366
Drug: Methotrexat
Normalized name: Methotrexat
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 to 25 mg/week
Study: NCT05004636
Drug: Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Normalized name: Aldex AN
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
Study: NCT04375202
Drug: Colchicine 1 MG Oral Tablet
Normalized name: colchicine 1 MG Oral Tablet
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
Study: NCT03205462
Drug: Fluorothyazinone 300 mg
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorothyazinone in a dosage of 300 mg (1 tablet)
Study: NCT03205462
Drug: Fluorothyazinone 600 mg
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
Study: NCT03205462
Drug: Fluorothyazinone 3900 mg
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total dose of Fluorothyazinone per treatment course is 3900 mg.
Study: NCT04153188
Drug: Oxymetazoline HCL 1% Cream
Normalized name: OXYMETAZOLINE HCL 1% CREAM,TOP
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
Study: NCT00858858
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of oral UDCA treatment 10 mg/kg qd
Study: NCT01480336
Drug: Amiodarone Plus Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 500mg by mouth twice daily
Study: NCT01480336
Drug: Amiodarone with Placebo
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: stabel dose of amiodarone as prescribed by cardiologist
Study: NCT00462228
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
Study: NCT00020605
Drug: naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01457716
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single inhalation
Study: NCT01457716
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single inhalation
Study: NCT01547455
Drug: Atorvastatin(Lipitor)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
Study: NCT00978211
Drug: DOTA-TOC Treatment
Normalized name: DOTA-TATE
DrugBank: Edotreotide (DB17969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment.
Study: NCT03711578
Drug: Tenalisib,
DrugBank: Tenalisib (DB15295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID, Orally